

Normal P axis, PR, rate & rhythm
p V1 - 1.0 mV or more negative
Q/S in V1 & V2
ST-T negative ANT/LAT/INF
T > -30 mV, ST > -0.5 mV

GlobalData»
MediPoint

**CORONARY STENTS –
GLOBAL ANALYSIS AND MARKET FORECASTS**

Executive Summary

The table below provides the key metrics for coronary stents in the 10 major markets (10MM) (US, France, Germany, Italy, Spain, UK, Japan, Brazil, China, and India) during the forecast period from 2013–2020.

Coronary Stents Market, Key Metrics in the 10MM, 2013–2020	
2013 Coronary Stents Market Sales (\$m)	
US	\$2,065.3m
EU	\$573.1m
APAC	\$2,123.3m
Brazil	\$124.0m
Total	\$4,885.7m
2013 Global Market Sales by Type of Stent (\$m)	
Drug-eluting stents (DES)	\$4,335.6m
Bare metal stents (BMS)	\$530.1m
Pipeline Assessment (Stage of Clinical Development)	
Number of stents in the early development stage	4
Number of stents in the preclinical stage	13
Number of stents in the early clinical stage	6
Number of stents in the late clinical stage	5
Key Events (2013–2020)	
	Level of Impact
(2013) Boston Scientific Corporation receives FDA approval for and launches the Promus PREMIER everolimus-eluting platinum-chromium (PtCr) stent in the US.	↑
(2013) Approval and launch of the next generation of DES, such as BioFreedom (Biosensors International) and Coroflex ISAR (B. Braun) in the EU	↑↑
(2013) Elixir Medical Corporation receives a CE Mark for the DESolve bioabsorbable stent (BAS) in the EU.	↑↑
(2014) MicroPort Scientific Corporation receives approval for Firehawk, the world's first targeted drug-eluting coronary stent system, in China.	↑↑
(2014) Approval and launch of the STENTYS sirolimus-eluting, self-expanding stent in the	↑

EU	
(2015) Commercial launch of the CE-Marked DESolve 100, a novolimus-eluting, thin-strut BAS, in the EU	↑
(2015–2016) Expected commercial launch of BAS, such as DREAMS by Biotronik and Fantom by REVA Medical, in the EU	↑↑
(2016–2017) Commercial launch of Absorb BVS in the US and APAC, including in Japan and China	↑↑↑
(2019–2020) Expected commercial launch of BAS, such as DREAMS by Biotronik and Fantom by REVA Medical, in the US	↑↑
2020 Coronary Stents Market Sales (\$m)	
US	\$1,849.9m
EU	\$555.2m
APAC	\$3,023.5m
Brazil	\$187.8m
Total	\$5,616.4m
Source: GlobalData	
CE Mark = Conformité Européenne (European Conformity) Mark	
EU = France, Germany, Italy, Spain, and UK	
APAC = Asia-Pacific (Japan, China, and India)	

Coronary Stent Sales by Region

Coronary stents can be used for a wide range of indications in coronary artery disease (CAD), including *de novo* lesions, small-vessel disease (SVD), bifurcation lesions, and tortuous and narrow lesions. Coronary stents can improve the clinical outcomes for all of these indications as well as quality of life for patients suffering from this debilitating disease.


The figure below shows the sales of coronary stents for treating CAD in each of the 10 countries covered in this report during the forecast period. In 2013, sales of DES and BMS in the 10MM were \$4.89 billion. GlobalData estimates the 2014 sales

Executive Summary

of DES and BMS in the 10MM to be \$4.99 billion. By 2020, sales of coronary stents, including bare metal and drug-eluting stents, will grow to \$5.62 billion, at a Compound Annual Growth Rate (CAGR) of 2.0%. To date, BAS have not received regulatory approval and been launched in the US, Japanese, and Chinese markets, but are expected to enter these markets in the near future.

Of the 10MM covered in the report, the US currently has and will continue to have the largest share in the coronary stents market. Together, the US, the 5EU countries, and Japan will account for 64% of the coronary stents market for BMS and DES in 2020. Collectively, the 5EU countries are forecast to have only 10% market share in the future. Among the emerging markets, China has captured significant market share, which is expected to increase in the future. The emerging markets, including Brazil, China, and India, are expected to demonstrate the greatest growth in the market over the forecast period and will serve as an outlet of expansion for stent manufacturers to increase their global presence.

Global Coronary Stents Market Revenue (\$bn), 2013 and 2020



Source: GlobalData

Global = US, EU (France, Germany, Italy, Spain, and UK), APAC (Japan, China, and India), and Brazil

The key drivers for the coronary stents market during the forecast period are:

- The rising prevalence of CAD in the major markets covered in this report
- The need for effective therapies that reduce the risk of complications, such as restenosis (re-narrowing of the coronary artery), chronic inflammation, and thrombosis, and the need for target lesion revascularization (TLR)

Executive Summary

associated with bare metal and drug-eluting stenting

- The cost savings for healthcare payers resulting from the reduced need for repeat revascularization procedures and prolonged dual antiplatelet therapy
- Reducing the need for stent-in-stent procedures and improving the technical feasibility of future interventions
- Innovations in stent technology with regard to the platform, material, and coating
- The increase in patients' disposable income and government insurance coverage in the emerging markets, such as China and India
- The approval and launch of BAS, such as the Absorb BVS, in the US, Japan, and China


Market Dynamics

Stenting for coronary applications has been widely adopted in clinical practice and is associated with improved outcomes. BMS and DES are effectively commodities, where the physician has a handful of stents from which to choose. Within the coronary stents market, DES currently dominate the market and will continue to do so throughout the forecast period, as they are considered the gold standard of treatment. The DES market is a vast and double-digit market, accounting for nearly 90% of the total coronary stent market, as shown in the figure below. In fact, DES sales for coronary applications are nearly eight times those of BMS market sales.

Given this large market potential and the rising prevalence of CAD worldwide, device manufacturers have focused primarily on the research and development (R&D) and commercialization of innovative DES systems. The larger market sales of DES can be attributed to physicians' extensive clinical experience and expertise in using these stents, improved outcomes, and the reduced need for repeat intervention. BMS are used in cases where the patient is not a good candidate to receive a DES, such as those planning to undergo other major surgeries in the near future.

Covered stents (CS) are used less often in practice and only in select cases, such as patients with artery perforations. BAS have only recently entered the market and are not widely adopted in clinical practice, due to the lack of clinical evidence and the high cost of these devices.

Global Coronary Stents Market Revenue (\$m) by Type of Stent, 2011–2020



Source: GlobalData

Global = US, EU (France, Germany, Italy, Spain, and UK), APAC (Japan, China, and India), and Brazil

Executive Summary

Technological Trends

Over the years, a plethora of BMS and DES have been developed, featuring innovative materials, designs, structures, coatings, and drug-elution components. The development and optimization of DES has become a primary focus for many stent manufacturers, where they utilize the BMS they have developed as the platform and foundation for their DES. These innovations in technology aim to ensure high radial strength and flexibility, low elastic recoil, optimal vessel coverage, minimal foreshortening, and rapid strut endothelialization.

Although stent technology has evolved over the years, several types of complications remain, such as late thrombosis and restenosis, negative vessel remodeling, delayed endothelialization and healing, lack of homogenous drug distribution, and the need for prolonged dual antiplatelet therapy. Therefore, low-profile drug-delivery systems need to be developed to reduce the risk of restenosis and thrombosis, and improve long-term patency. Effective therapies also need to be developed to treat complex lesions and challenging patient populations, such as chronic total occlusions (CTOs), long lesions, acute myocardial infarction (AMI) (heart attack), and diabetes mellitus.

Emerging stent technologies in the coronary stent market, including BAS and the third generation of DES with biodegradable polymer/polymer-free coatings, aim to address these unmet needs. However, these emerging technologies have only recently entered the market and will encounter

strong competition from the contemporary stents. The third generation of DES has been developed to eliminate concerns associated with the permanent polymer coating, which is a cause of late and very late stent thrombosis. Drug-eluting BAS represent the fourth generation of DES in the evolution of DES technology. Given that the stent scaffold degrades over a period of time, BAS offer several benefits, including a reduced risk of restenosis, avoiding the implantation of multiple layers of metal inside the vessel, improving the feasibility of future interventions, and enabling for late lumen gain.

Key Players in the Global Coronary Stents Market

The coronary stents market is a vast and dynamic market that is saturated with numerous players worldwide, as illustrated in the figure below. The competitive landscape consists of large, mid-size, and small companies that have developed different types of coronary stents to target various indications, such as *de novo* lesions and bifurcation lesions. The coronary stents market is largely dominated by a few key players, including Abbott Vascular, Medtronic, and Boston Scientific, followed by Biosensors International and Terumo Corporation.

Companies such as B. Braun, Sahajanand Medical Technologies, MicroPort Scientific Corporation, and Balton are potential competitors to these large corporations, as they develop innovative coronary stent platforms. As the next generation of DES and


Executive Summary

BAS enter the market, the current key players will need to retain and acquire market share by improving the clinical performance of their existing products. In addition, they will need to expand into or increase their presence in the emerging markets in order to take revenue away from their competitors in the future.


The top players in the coronary stent market offer a broad product portfolio with regard to the type of stent and the number of products within each stent category. Within this market, stent manufacturers can customize the type of stent they develop for specific types of lesions in the coronary vasculature.

Global Coronary Stents (BMS and DES) Market for Treating CAD, Company Share Analysis (%), 2013

2013 - BMS Company Share Analysis (%)



2013 - DES Company Share Analysis (%)



Source: GlobalData

"Others" category includes Alvimedica, Balton, Biotronik, Envision Scientific, Innovative Health Technologies, Meril Life Science, MicroPort Scientific Corporation, Minvasys, OrbusNeich Medical, Sahajanand Medical Technologies, Translumina, and Vascular Concepts.

Future Outlook

Each year, millions of individuals worldwide are affected by CAD. Given the high burden of the disease, it is important to develop innovative technologies that can improve outcomes and disease management. Currently, DES are widely adopted in clinical practice, given the clinical evidence, improved outcomes, and physician experience with using these devices. In the US and 5EU, the coronary stents market value is expected

to decline slowly in the future, given the decline in the average selling price (ASP) and number of BMS and DES used per procedure. As medical costs continue to rise, healthcare providers are implementing cost-containment policies and "appropriateness criteria" to reduce costs and overstenting.

Executive Summary

Unlike in the west, the coronary stents market in the APAC and South American regions is expected to increase and demonstrate steady growth in the future. The APAC countries, including Japan, China, and India, have diverse populations, ethnicities, and clinical practices. Most device manufacturers regard Japan and China as their chief targets, due to their economic growth, pricing structure, and vast populations. In particular, China, with its high proportion of aging individuals and procedure volume, is expected to become a prime market for coronary stents.

Many stent manufacturers have ventured into the R&D of BAS, which is a high-growth market segment. However, BAS technology is in the early stages, where robust, long-term clinical evidence of its therapeutic benefits needs to be shown. Currently, the adoption of BAS in the clinical setting is low, which is attributable to the lack of clinical data and appropriate reimbursement, as well as the high cost of these devices. In real-world practice, the majority of patients with CAD are treated with DES, and this will continue in the future. In addition, the development and commercialization of the next generation of DES with bioresorbable polymer coatings, polymer-free coatings, and innovative platforms indicates the continued value of DES in the coronary market.

What Do Physicians Think?

- Physicians interviewed by GlobalData believe that coronary stents will continue to be widely adopted for treating patients with CAD, especially in the emerging markets. DES are the gold standard of treatment for CAD and will continue to dominate the market in the future. Device manufacturers have developed innovative stent platforms to improve outcomes and the patient prognosis.

“Coronary stents will absolutely continue to be widely adopted in the future; just look at the numbers....In the emerging markets, as logistical issues with reimbursement and development issues are addressed, we will see increased adoption in the future. Markets like China and India are huge markets with huge populations, where stenting is still underused. I do see a trend towards an increase in coronary stenting procedures in the future, especially in the emerging markets....”

Key Opinion Leader

“I think BMS will almost disappear in five years’ time; DES will be the gold standard, and adoption of [the Absorb] BVS will increase with its entry into the market. Stents design will improve with the incorporation of limus drugs, [the] development of innovative platforms, and reimbursement.”

Key Opinion Leader

Executive Summary

- Coronary stents such as DES and BMS are effectively commodities, where physicians have a handful of stents from which to choose. The cost of the device plays an important role in the adoption of each type of stent.

"Most of the vendors retail a similar stent product, where there is little difference between them. It comes down to price."

Key Opinion Leader

- Physicians are cautiously optimistic about BAS technology with regard to the adoption of these devices in real-world practice. Currently, BAS are not widely adopted in clinical practice, which can be attributed to the lack of clinical data and reimbursement, and well as the high cost of these devices.

"I think the Holy Grail is having a completely absorbable stent. No doctor or patient will ever say that they want permanent implants. Having a completely degradable stent is the best thing that you can have.....So, I feel the next development has to be a better [more] absorbable stent."

Key Opinion Leader

"I believe in the concept of bioabsorbable stents, but I think that it has not been proven enough to be fully incorporated into practice. I think they are likely to present benefits and may be used in the future as the first line of therapy for certain indications, compared with the currently used second-generation DES. At present, I do not see any clinical benefit [of BAS] compared to the contemporary coronary stents..., but we don't have data supporting that [the use of BAS], and I think we will not have it in the next few years. I believe in the potential of BAS technology, but it has not been proven yet."

Key Opinion Leader

- The current design of BAS platforms, such as the Absorb Bioresorbable Vascular Scaffold (BVS), needs to be improved in terms of its deliverability and performance compared with DES and BMS.

"There are some limitations with the currently available BAS because of product strength. The current BVS scaffolds have big struts of about 140 microns. So, if you put that in a 2mm vessel, I think that the limiting loss will be quite big. Maybe when the device will be improved and we arrive at the next generation of BVS, we can tackle these kinds of lesions. However, I do not think we will start with that within the next few months."

Key Opinion Leader

Executive Summary

"The acute results are not good with the Absorb BVS because the stent struts are thicker than [those of the] contemporary stents, where you do not get optimal expansion of the lesion....There are concerns that the flow is not streamline flow, and there is an increased chance for thrombosis. That is what we have seen with the results, where [the] stent thrombosis rates of the Absorb BVS are a little higher than [those of] the current gold-standard DES."

Key Opinion Leader

- As cost-containment policies are implemented, the widespread adoption of expensive coronary stent technologies is questioned.

"I think price and access to devices are going to be issues. The current financial environment in healthcare is very uncertain....I would not be surprised that in a year or two, we will be told to prove [that] using one device over another [is better] for cost-containment purposes."

Key Opinion Leader

"Cost and availability are what will drive the usage of stents. There is a lot of excitement about the technology, and [it] has a lot of potential, where a lot of people are willing to test BAS technology. However, I think that the cost will be a big issue here, and [also, the] logistics."

Key Opinion Leader

Table of Contents

1 Table of Contents

1	Table of Contents	10
1.1	List of Tables	20
1.2	List of Figures	28
2	Introduction	31
2.1	Catalyst.....	32
2.2	Related Reports	33
3	Industry Overview	34
3.1	Disease Overview	34
3.2	Clinical Outcomes	35
3.2.1	Treatment Guidelines	35
3.2.2	Treatment Modalities	36
3.3	Procedure Trends	50
3.3.1	United States.....	52
3.3.2	European Union	53
3.3.3	Asia-Pacific	55
3.3.4	Brazil.....	57
3.4	Market Access	58
3.4.1	Regulatory Process.....	59
3.4.2	Physician Decision-Making Process	65
3.4.3	Role of Group Purchasing Organizations	69
3.4.4	Lack of Clinical Data.....	72

Table of Contents

3.4.5	Regional-Level Control.....	74
3.4.6	Cost Considerations.....	75
3.4.7	Reimbursement Trends.....	80
3.5	Regulatory Issues/Recalls.....	91
3.5.1	Regulatory Issues	91
3.5.2	Product Recalls.....	92
3.6	Mergers and Acquisitions/ Key Partnerships	92
3.6.1	Medtronic and Covidien.....	92
3.6.2	Arterial Remodeling Technologies and Terumo Corporation	93
3.6.3	MicroPort Scientific Corporation and Cordis Corporation.....	93
3.6.4	Alvimedica and CID.....	94
3.6.5	ITGI Medical and Vascular Solutions.....	94
3.6.6	Terumo Corporation and Onset Medical Corporation	95
3.6.7	Atrium Medical and Getinge Group	95
3.6.8	C.R. Bard and ClearStream Technologies.....	95
3.6.9	Biosensors International and Devax, CardioMind, and JW Medical Systems.....	96
3.6.10	CeloNova Biosciences and Nexeon MedSystems	97
3.6.11	Medtronic and Invatec.....	97
3.6.12	Micell Technologies and Maxcor Lifescience.....	98
3.6.13	Boston Scientific Corporation and Guidant Corporation.....	98
3.6.14	Abbott Vascular and Guidant Corporation	98
3.6.15	Kaneka Corporation and Fujisawa Pharmaceuticals.....	99
3.7	Economic Impact of Coronary Artery Disease.....	99

Table of Contents

3.7.1	United States.....	100
3.7.2	European Union	102
3.7.3	Asia-Pacific	103
3.7.4	Brazil.....	104
3.8	Treatment Costs for Coronary Artery Disease.....	105
4	Unmet Needs.....	107
4.1	Need for Better Clinical Outcomes in Specific Lesions	107
4.1.1	Chronic Total Occlusions.....	107
4.1.2	Small-Vessel Coronary Lesions.....	108
4.1.3	Heavily-Calcified and Uncrossable/Undilatable Lesions	109
4.1.4	Bifurcation Lesions	109
4.1.5	Saphenous Vein Graft Intervention.....	110
4.2	Eliminating Mechanisms of Failure With Balloon Angioplasty.....	111
4.3	Late Myocardial Infarction After Stenting.....	111
4.4	Eliminating the Permanent Polymer	112
4.5	In-Stent Restenosis.....	113
4.6	Stent-In-Stent Procedures.....	115
4.7	Prolonged Dual Antiplatelet Therapy.....	116
4.8	Lack of Homogenous Drug Distribution.....	117
4.9	Delayed Stent Endothelialization.....	117
4.10	Negative Vessel Remodeling	118
4.11	Need for Effective Therapy for Specific Patient Populations.....	118
4.12	Addressing the Complications of Coronary Artery Bypass Grafting	119

Table of Contents

5	Market Opportunity Analysis	120
5.1	Improve Stent Design/Platform	120
5.1.1	Stent Coating Technology	121
5.1.2	Bioabsorbable Stent Technology.....	123
5.1.3	Antiproliferative Drug and Elution Kinetics.....	124
5.2	Hybrid Stent Systems.....	126
5.3	Effective Therapies for Challenging Coronary Indications	127
5.3.1	Chronic Total Occlusions.....	127
5.3.2	Small-Vessel Disease	127
5.3.3	Bifurcation Lesions.....	128
5.3.4	Diffuse Atherosclerotic Disease.....	129
5.3.5	Saphenous Vein Graft Intervention.....	129
5.3.6	Acute Myocardial Infarction	129
5.4	Target Challenging Patient Populations	130
5.5	Emerging Markets.....	131
6	Market Drivers, Barriers, and Substitutes.....	132
6.1	Market Drivers.....	132
6.1.1	Rising Prevalence of Disease.....	133
6.1.2	Viable Treatment for Challenging Coronary Indications.....	134
6.1.3	Innovations in Stent Technology.....	135
6.1.4	Development of Bioabsorbable Stents.....	137
6.1.5	Reduce the Need for Prolonged Dual Antiplatelet Therapy.....	139
6.1.6	Potential Cost Savings	140

Table of Contents

6.1.7	Use of Imaging Modalities for Accurate Stent Placement	141
6.1.8	Adoption of Stents in the Emerging Markets.....	141
6.1.9	Launch of Bioabsorbable Stents in US and Japan.....	142
6.2	Market Barriers	142
6.2.1	Concerns Regarding Overstenting	142
6.2.2	Post-Procedural Complications of Drug-Eluting Stenting.....	143
6.2.3	Risk of Perioperative Adverse Cardiac Events Post-Stenting	143
6.2.4	Slow Adoption of Bioabsorbable Stents.....	144
6.2.5	Lack of Reimbursement	149
6.2.6	Healthcare Cost-Cutting and Reimbursement	150
6.2.7	Availability of Venture Capital.....	151
6.2.8	Medical Device Excise Tax.....	152
6.3	Market Substitutes	152
6.3.1	Drug-Eluting Balloons.....	152
6.3.2	Liquid Drug Delivery Catheter	153
7	Competitive Assessment	155
7.1	Overview.....	155
7.2	Trends in Coronary Stent Technology Development	156
7.2.1	Development of Bare Metal Stents	156
7.2.2	Development of Drug-Eluting Stents	158
7.2.3	Development of Bioabsorbable Stents.....	161
7.2.4	Development of Covered Stents.....	162
7.2.5	Coronary Stent Technology SWOT Analysis	163

Table of Contents

7.3	Global Company Market Share	164
7.3.1	Bare Metal Stent Market Share	164
7.3.2	Drug-Eluting Stent Market Share	165
7.4	Regional Company Market Share	166
7.4.1	US Market Share	166
7.4.2	EU Market Share	168
7.4.3	APAC Market Share	170
7.4.4	Brazil Market Share	172
8	Pipeline Products	175
8.1	Overview	175
8.2	Pipeline by Stage of Development	175
8.3	Pipeline Product Profiles	178
8.3.1	Bioabsorbable Stents	178
8.3.2	Other Types of Vascular Stents	189
9	Clinical Trial Analysis	195
9.1	Overview	195
9.2	Clinical Trials to Watch	195
9.2.1	Evaluating the Latest and New Generation of Drug-Eluting Stents	195
9.2.2	Bioabsorbable Stent Clinical Trials	197
9.2.3	Evaluating Stenting in Challenging Coronary Indications/Patient Populations	201
9.2.4	Targeting Patient Populations in the APAC Region	203
10	Current and Future Players	205
10.1	Overview	205

Table of Contents

10.2	Trends in Corporate Strategy	205
10.3	Company Profiles.....	208
10.3.1	Abbott Vascular	208
10.3.2	Boston Scientific Corporation	214
10.3.3	Medtronic	221
10.3.4	Alvimedica.....	227
10.3.5	Amaranth Medical	231
10.3.6	amg International	234
10.3.7	Arterial Remodeling Technologies.....	238
10.3.8	B. Braun.....	241
10.3.9	Balton.....	244
10.3.10	Biosensors International.....	249
10.3.11	Biotronik	253
10.3.12	Blue Medical.....	258
10.3.13	Cardionovum.....	262
10.3.14	C.R. Bard	266
10.3.15	Elixir Medical Corporation.....	270
10.3.16	eucatech AG	275
10.3.17	Hexacath.....	279
10.3.18	IRAMED	282
10.3.19	JW Medical Systems	285
10.3.20	Kyoto Medical Planning.....	288
10.3.21	Lepu Medical Technology.....	292

Table of Contents

10.3.22 MicroPort Scientific Corporation	296
10.3.23 Minvasys	300
10.3.24 MIV Therapeutics	304
10.3.25 Opto Circuits	308
10.3.26 OrbusNeich Medical	312
10.3.27 Relisys Medical Devices.....	316
10.3.28 REVA Medical	320
10.3.29 Sahajanand Medical Technologies.....	323
10.3.30 STENTYS	327
10.3.31 Terumo Corporation	331
10.3.32 Translumina	335
10.3.33 Vascular Concepts	339
10.3.34 Other Companies	343
11 Market Outlook	355
11.1 By Market Segment.....	355
11.1.1 Overview	355
11.1.2 Drug-Eluting Stent Market	356
11.1.3 Bare Metal Stent Market.....	358
11.1.4 Emerging Stent Technologies	359
11.2 By Indication	361
11.3 By Geography	362
11.3.1 Overview	362
11.3.2 United States.....	365

Table of Contents

11.3.3	5EU.....	368
11.3.4	Asia-Pacific.....	381
11.3.5	Brazil.....	392
12	Appendix.....	395
12.1	Bibliography.....	395
12.2	Abbreviations.....	419
12.3	Report Methodology.....	426
12.3.1	Overview.....	426
12.3.2	Coverage.....	426
12.3.3	Secondary Research.....	426
12.4	Physicians and Specialists Included in This Study.....	428
12.4.1	Praveen Chandra, MD, DM, FESC, FSCAI, FAPSCI.....	428
12.4.2	Bernardo Cortese, MD, FESC.....	428
12.4.3	Ricardo A. Costa, MD.....	428
12.4.4	Thomas Cuisset, MD, PhD, FESC.....	428
12.4.5	Nobuyuki Komiyama, MD, PhD, FACC, FJCC.....	428
12.4.6	Roger J. Laham, MD.....	428
12.4.7	Mark W. Mewissen, MD.....	428
12.4.8	Gary S. Mintz, MD.....	428
12.4.9	Tudor C. Poerner, MD.....	429
12.4.10	David Ramsdale, MD, PhD.....	429
12.4.11	Gregory A. Sgueglia, MD, PhD.....	429
12.4.12	Madhukar Shahi, MD.....	429

Table of Contents

12.4.13 Takehiro Yamashita, MD, PhD, FACC.....	429
12.5 Primary Research	430
12.5.1 Primary Research – Key Opinion Leader Interviews.....	430
12.5.2 Primary Research Interviews– Physician and Industry Participants.....	430
12.5.3 Physician Survey	431
12.5.4 Expert Panel Validation	432
12.6 Forecasting Methodology.....	433
12.7 About the Authors	435
12.7.1 Analysts	435
12.7.2 Global Head of Healthcare.....	436
12.8 About MediPoint.....	437
12.9 About GlobalData.....	437
12.10 Disclaimer.....	437

Table of Contents

1.1 List of Tables

Table 1:	ACCF/AHA Treatment Guidelines to Improve the Symptoms of CAD*	36
Table 2:	Types of CABG	39
Table 3:	Complications of CABG	40
Table 4:	Drugs Incorporated Into DES	43
Table 5:	Types of Lesions Treated Using Atherectomy	47
Table 6:	GPOs in the US and EU	70
Table 7:	Medicare National Average of Inpatient Hospital Payment for CAD Therapeutic Procedures, 2013–2015	81
Table 8:	Reimbursement Classification of Medical Devices in Japan	88
Table 9:	Direct and Indirect Healthcare Costs of CAD	100
Table 10:	Healthcare Expenditures (\$bn, 2008\$) for CAD in the US, 2011–2020	101
Table 11:	Healthcare Expenditures (\$bn) for CAD in the 5EU, 2006	103
Table 12:	US Mean Hospital Costs* (\$US) for Cardiac Revascularization Procedures, 2011–2020	106
Table 13:	Coronary Stent Technology SWOT Analysis, 2014	163
Table 14:	Global Coronary Stent Pipeline Products, 2014	177
Table 15:	ART18Z SWOT Analysis, 2014	179
Table 16:	DREAMS SWOT Analysis, 2014	180
Table 17:	Fantom SWOT Analysis, 2014	181
Table 18:	Fortitude SWOT Analysis, 2014	182
Table 19:	Ideal BioStent SWOT Analysis, 2014	183
Table 20:	Igaki-Tamai Stent SWOT Analysis, 2014	185
Table 21:	ON-AVS SWOT Analysis, 2014	186
Table 22:	Other Companies Developing BAS, 2014	189

Table of Contents

Table 23: FOCUS np Eluting Stent SWOT Analysis, 2014.....	190
Table 24: STENTYS Sirolimus-Eluting Stent SWOT Analysis, 2014	191
Table 25: Svelte Drug-Eluting Stent SWOT Analysis, 2014	193
Table 26: Clinical Trials Evaluating the Latest and New Generation of DES, 2014.....	196
Table 27: Clinical Trials Evaluating Stenting in Challenging CAD Indications/Patient Populations, 2014	202
Table 28: Clinical Trials Evaluating Coronary Stenting in APAC Patient Populations, 2014.....	204
Table 29: Abbott Vascular Company Profile	208
Table 30: Abbott Vascular Coronary Stent Marketed Products	210
Table 31: Abbott Vascular Coronary Stent Product Portfolio SWOT Analysis, 2014.....	213
Table 32: Abbott Vascular SWOT Analysis, 2014.....	214
Table 33: Boston Scientific Corporation Company Profile.....	215
Table 34: Boston Scientific Coronary Stent Marketed Products	217
Table 35: Boston Scientific Coronary Stent Product Portfolio SWOT Analysis, 2014.....	220
Table 36: Boston Scientific Corporation SWOT Analysis, 2014.....	221
Table 37: Medtronic Company Profile	222
Table 38: Medtronic Coronary Stent Marketed Products.....	224
Table 39: Medtronic Coronary Stent Product Portfolio SWOT Analysis, 2014	226
Table 40: Medtronic SWOT Analysis, 2014	227
Table 41: Alvimedica Company Profile.....	228
Table 42: Alvimedica Coronary Stent Marketed Products	229
Table 43: Alvimedica Coronary Stent Product Portfolio SWOT Analysis, 2014.....	230
Table 44: Alvimedica SWOT Analysis, 2014.....	231
Table 45: Amaranth Medical Company Profile.....	232
Table 46: Amaranth Medical Coronary Stent Pipeline Product.....	232

Table of Contents

Table 47: Amaranth Medical Coronary Stent Product Portfolio SWOT Analysis, 2014	233
Table 48: Amaranth Medical SWOT Analysis, 2014	233
Table 49: amg International Company Profile.....	234
Table 50: amg International Coronary Stent Marketed Products.....	236
Table 51: amg International Coronary Stent Product Portfolio SWOT Analysis, 2014.....	237
Table 52: amg International SWOT Analysis, 2014.....	238
Table 53: Arterial Remodeling Technologies Company Profile.....	239
Table 54: Arterial Remodeling Technologies Coronary Stent Pipeline Product.....	239
Table 55: Arterial Remodeling Technologies Coronary Stent Product Portfolio SWOT Analysis, 2014	240
Table 56: Arterial Remodeling Technologies SWOT Analysis, 2014	240
Table 57: B. Braun Company Profile	241
Table 58: B. Braun Coronary Stent Marketed Products	242
Table 59: B. Braun Coronary Stent Product Portfolio SWOT Analysis, 2014.....	243
Table 60: B. Braun SWOT Analysis, 2014.....	244
Table 61: Balton Company Profile.....	245
Table 62: Balton Coronary Stent Marketed Products	246
Table 63: BALTON Coronary Stent Product Portfolio SWOT Analysis, 2014.....	248
Table 64: Balton SWOT Analysis, 2014.....	248
Table 65: Biosensors International Company Profile	249
Table 66: Biosensors International Coronary Stent Marketed Products.....	251
Table 67: Biosensors International Coronary Stent Product Portfolio SWOT Analysis, 2014	252
Table 68: Biosensors International SWOT Analysis, 2014	253
Table 69: Biotronik Company Profile	254
Table 70: Biotronik Coronary Stent Marketed and Pipeline Products	255

Table of Contents

Table 71: Biotronik Coronary Stent Product Portfolio SWOT Analysis, 2014	257
Table 72: Biotronik SWOT Analysis, 2014	258
Table 73: Blue Medical Company Profile	259
Table 74: Blue Medical Coronary Stent Marketed Products	260
Table 75: Blue Medical Coronary Stent Product Portfolio SWOT Analysis, 2014	261
Table 76: Blue Medical SWOT Analysis, 2014	262
Table 77: Cardionovum Company Profile	263
Table 78: Cardionovum Coronary Stent Marketed and Pipeline Products	264
Table 79: Cardionovum Coronary Stent Product Portfolio SWOT Analysis, 2014	265
Table 80: Cardionovum SWOT Analysis, 2014	266
Table 81: C.R. Bard Company Profile	267
Table 82: ClearStream Technologies Coronary Stent Marketed Products	268
Table 83: C.R. Bard Coronary Stent Product Portfolio SWOT Analysis, 2014	269
Table 84: C.R. Bard SWOT Analysis, 2014	270
Table 85: Elixir Medical Corporation Company Profile	271
Table 86: Elixir Medical Corporation Coronary Stent Marketed Products	272
Table 87: Elixir Medical Corporation Coronary Stent Product Portfolio SWOT Analysis, 2014	274
Table 88: Elixir Medical Corporation SWOT Analysis, 2014	275
Table 89: eucatech Profile	276
Table 90: eucatech Coronary Stent Marketed Products	277
Table 91: eucatech Coronary Stent Product Portfolio SWOT Analysis, 2014	278
Table 92: eucatech SWOT Analysis, 2014	279
Table 93: Hexacath Company Profile	280
Table 94: Hexacath Coronary Stent Marketed Products	281

Table of Contents

Table 95: Hexacath Coronary Stent Product Portfolio SWOT Analysis, 2014.....	281
Table 96: Hexacath SWOT Analysis, 2014.....	282
Table 97: IRAMED Company Profile	282
Table 98: IRAMED Coronary Stent Marketed Products	283
Table 99: IRAMED Coronary Stent Product Portfolio SWOT Analysis, 2014	284
Table 100: IRAMED SWOT Analysis, 2014	285
Table 101: JW Medical Systems Company Profile	286
Table 102: JW Medical Systems Coronary Stent Marketed Product	286
Table 103: JW Medical Systems' Coronary Stent Product Portfolio SWOT Analysis, 2014	287
Table 104: JW Medical Systems SWOT Analysis, 2014	288
Table 105: Kyoto Medical Planning Company Profile	289
Table 106: Kyoto Medical Planning Coronary Stent Pipeline Product	290
Table 107: Kyoto Medical Planning Coronary Stent Product Portfolio SWOT Analysis, 2014	291
Table 108: Kyoto Medical Planning SWOT Analysis, 2014	291
Table 109: Lepu Medical Technology Company Profile	292
Table 110: Lepu Medical Technology Coronary Stent Marketed and Pipeline Products	294
Table 111: Lepu Medical Technology Coronary Stent Product Portfolio SWOT Analysis, 2014	295
Table 112: Lepu Medical Technology SWOT Analysis, 2014	296
Table 113: MicroPort Scientific Corporation Company Profile	297
Table 114: MicroPort Scientific Corporation Coronary Stent Marketed Products	298
Table 115: MicroPort Scientific Corporation Coronary Stent Product Portfolio SWOT Analysis, 2014	299
Table 116: MicroPort Scientific Corporation SWOT Analysis, 2014	300
Table 117: Minvasys Company Profile	301
Table 118: Minvasys Coronary Stent Marketed and Pipeline Products	302

Table of Contents

Table 119: Minvasys Coronary Stent Product Portfolio SWOT Analysis, 2014	303
Table 120: Minvasys SWOT Analysis, 2014	304
Table 121: MIV Therapeutics Company Profile	305
Table 122: MIV Therapeutics Coronary Stent Marketed Products	306
Table 123: MIV Therapeutics Coronary Stent Product Portfolio SWOT Analysis, 2014	307
Table 124: MIV Therapeutics SWOT Analysis, 2014	308
Table 125: Opto Circuits Company Profile	309
Table 126: Opto Circuits Coronary Stent Marketed Products	310
Table 127: Opto Circuits Coronary Stent Product Portfolio SWOT Analysis, 2014	311
Table 128: Opto Circuits SWOT Analysis, 2014	312
Table 129: OrbusNeich Medical Company Profile	313
Table 130: OrbusNeich Medical Coronary Stent Marketed and Pipeline Products	314
Table 131: OrbusNeich Medical Coronary Stent Product Portfolio SWOT Analysis, 2014	315
Table 132: OrbusNeich Medical SWOT Analysis, 2014	316
Table 133: Relisys Medical Devices Company Profile	317
Table 134: Relisys Medical Devices Coronary Stent Marketed Products	318
Table 135: Relisys Medical Devices Coronary Stent Product Portfolio SWOT Analysis, 2014	319
Table 136: Relisys Medical Devices SWOT Analysis, 2014	320
Table 137: REVA Medical Company Profile	321
Table 138: REVA Medical Coronary Stent Pipeline Product	321
Table 139: REVA Medical Coronary Stent Product Portfolio SWOT Analysis, 2014	322
Table 140: REVA Medical SWOT Analysis, 2014	323
Table 141: Sahajanand Medical Technologies Company Profile	324
Table 142: Sahajanand Medical Technologies Coronary Stent Marketed and Pipeline Products	325

Table of Contents

Table 143: Sahajanand Medical Technologies Coronary Stent Product Portfolio SWOT Analysis, 2014	326
Table 144: Sahajanand Medical Technologies SWOT Analysis, 2014	327
Table 145: STENTYS Company Profile.....	328
Table 146: STENTYS Coronary Stent Marketed and Pipeline Products.....	329
Table 147: STENTYS Coronary Stent Product Portfolio SWOT Analysis, 2014	330
Table 148: STENTYS SWOT Analysis, 2014	331
Table 149: Terumo Corporation Company Profile.....	332
Table 150: Terumo Corporation Coronary Stent Marketed and Pipeline Products.....	333
Table 151: Terumo Corporation Coronary Stent Product Portfolio SWOT Analysis, 2014	334
Table 152: Terumo Corporation SWOT Analysis, 2014	335
Table 153: Translumina Company Profile.....	336
Table 154: Translumina Coronary Stent Marketed Products.....	337
Table 155: Translumina Coronary Stent Product Portfolio SWOT Analysis, 2014	338
Table 156: Translumina SWOT Analysis, 2014	338
Table 157: Vascular Concepts Company Profile.....	339
Table 158: Vascular Concepts Coronary Stent Marketed Products.....	340
Table 159: Vascular Concepts Coronary Stent Product Portfolio SWOT Analysis, 2014	341
Table 160: Vascular Concepts SWOT Analysis, 2014	342
Table 161: Other Companies in the Coronary Stent Market, North America, 2014	343
Table 162: Other Companies in the Coronary Stent Market, EU, 2014	348
Table 163: Other Companies in the Coronary Stent Market, APAC, 2014.....	351
Table 164: Other Companies in the Coronary Stent Market, South Africa and South America, 2014.....	354
Table 165: Global Coronary Stent Sales (\$m) Forecast, by Segment, 2011–2020	355
Table 166: Global DES Sales (\$m) Forecast, 2011–2020.....	356

Table of Contents

Table 167: Global BMS Sales (\$m) Forecast, 2011–2020	358
Table 168: Coronary Stents Market Sales (\$m) Forecast for the United States, 2011–2020	365
Table 169: EU Coronary Stent Sales (\$m) Forecast, by Segment, 2011–2020	368
Table 170: Coronary Stents Market Sales (\$m) Forecast for France, 2011–2020	370
Table 171: Coronary Stents Market Sales (\$m) Forecast for Germany, 2011–2020	372
Table 172: Coronary Stents Market Sales (\$m) Forecast for Italy, 2011–2020	375
Table 173: Coronary Stents Market Sales (\$m) Forecast for Spain, 2011–2020	377
Table 174: Coronary Stents Market Sales (\$m) Forecast for the UK, 2011–2020	379
Table 175: APAC Coronary Stent Sales (\$m) Forecast, by Segment, 2011–2020	382
Table 176: Coronary Stents Market Sales (\$m) Forecast for Japan, 2011–2020	383
Table 177: Coronary Stents Market Sales (\$m) Forecast for China, 2011–2020	386
Table 178: Coronary Stents Market Sales (\$m) Forecast for India, 2011–2020	389
Table 179: Coronary Stents Market Sales (\$m) Forecast for Brazil, 2011–2020	392
Table 180: Primary Research Interviews Completed	431
Table 181: Physicians Surveyed, By Country	432

Table of Contents

1.2 List of Figures

Figure 1: Pathophysiology of CAD.....	34
Figure 2: CAD Treatment Modalities.....	37
Figure 3: Percentage of Patients with CAD Who Receive Each Therapy Option Only, Global, 2012 and 2019 (N=58).....	38
Figure 4: Percentage of Patients with CAD Who Receive Each Type of PCI Only, Global, 2012 and 2019 (N=58).....	41
Figure 5: Types of Stents Used to Treat CAD.....	42
Figure 6: Example of a BMS.....	43
Figure 7: Example of a DEB.....	46
Figure 8: Types of Atherectomy.....	48
Figure 9: Global Coronary Stenting Procedure Volume, 2011–2020	51
Figure 10: US Coronary Stenting Procedure Volume, 2011–2020	52
Figure 11: 5EU Coronary Stenting Procedure Volume, 2011–2020.....	54
Figure 12: APAC Coronary Stenting Procedure Volume, 2011–2020	56
Figure 13: Brazil Coronary Stenting Procedure Volume, 2011–2020.....	58
Figure 14: Healthcare Expenditures (\$bn, 2008\$) for CAD in the US, 2011–2020.....	101
Figure 15: US Mean Hospital Costs* (\$US) for Cardiac Revascularization Procedures, 2011–2020.....	106
Figure 16: Percentage of CAD Patients with ISR, Global, 2012 and 2018 (N=58)	114
Figure 17: Percentage of CAD Patients Who Receive Stent-In-Stent Procedures, Global, 2012 and 2018 (N=58).....	116
Figure 18: Interventional Cardiologists' Ranking of the Importance of Each Therapy Attribute in Adopting Stents for the Treatment of CAD, Global, 2013 (N=101)	121
Figure 19: Global Coronary Stents Market Value Share (%), 2013 and 2020	156
Figure 20: Global BMS Company Market Share (%), 2013	165

Table of Contents

Figure 21: Global DES Company Market Share (%), 2013.....	166
Figure 22: US Market Share for BMS (%), 2013	167
Figure 23: US Market Share for DES (%), 2013.....	168
Figure 24: EU Market Share for BMS (%), 2013	169
Figure 25: EU Market Share for DES (%), 2013.....	170
Figure 26: APAC Market Share for BMS (%), 2013.....	171
Figure 27: APAC Market Share for DES (%), 2013	172
Figure 28: Brazil Market Share for BMS (%), 2013	173
Figure 29: Brazil Market Share for DES (%), 2013.....	174
Figure 30: Global Coronary Stent Pipeline Products by Stage of Development, 2014	176
Figure 31: Global Coronary Stents Market Revenue (\$m), 2011–2020	356
Figure 32: Global DES Market Revenue (\$m), 2011–2020	357
Figure 33: Global BMS Market Revenue (\$m), 2011–2020	359
Figure 34: Percentage of Patients (%) Treated with Each Type of Coronary Stent Only, Global, 2013 and 2020 (N=101)	361
Figure 35: Percentage of Patients (%) Treated with Coronary Stents for Each Indication, Global, 2013 and 2020 (N=101)	362
Figure 36: Global Coronary Stents Market Revenue (\$bn), 2013 and 2020.....	364
Figure 36: US Sales (\$m) Forecast for Coronary Stents, 2011–2020	366
Figure 38: EU Sales (\$m) Forecast for Coronary Stents, 2011–2020	369
Figure 39: French Sales (\$m) Forecast for Coronary Stents, 2011–2020	371
Figure 40: German Sales (\$m) Forecast for Coronary Stents, 2011–2020	373
Figure 41: Italian Sales (\$m) Forecast for Coronary Stents, 2011–2020	375
Figure 42: Spanish Sales (\$m) Forecast for Coronary Stents, 2011–2020	377
Figure 43: UK Sales (\$m) Forecast for Coronary Stents, 2011–2020	380

Table of Contents

Figure 44: APAC Sales (\$m) Forecast for Coronary Stents, 2011–2020	382
Figure 45: Japanese Sales (\$m) Forecast for Coronary Stents, 2011–2020.....	384
Figure 46: Chinese Sales (\$m) Forecast for Coronary Stents, 2011–2020	388
Figure 47: Indian Sales (\$m) Forecast for Coronary Stents, 2011–2020	390
Figure 48: Brazilian Sales (\$m) Forecast for Coronary Stents, 2011–2020	393

Introduction

2 Introduction

Coronary artery disease (CAD) is a global public health and socioeconomic problem that affects millions of lives each year. Percutaneous coronary interventions (PCIs), such as stenting and angioplasty, have been widely adopted worldwide to treat a range of CAD indications. The coronary stent market is a dynamic and competitive one that is saturated with numerous players trying to gain share by developing innovative technologies. Coronary stents, which include bare metal, drug-eluting, covered, and bioabsorbable stents (BAS), can be used for a range of indications in CAD, including *de novo* stenosis, acute myocardial infarction (AMI) (heart attack), bifurcation lesions, SVD, saphenous vein grafts (SVGs), left main coronary artery disease (LMCAD) and chronic total occlusions (CTOs).

Among the different types of stents, drug-eluting stents (DES) are considered to be the gold standard of treatment and will continue to dominate the global coronary stents market in the future. Since the development of the first generation of DES, manufacturers have focused on optimizing and developing innovative low-profile platforms, stent coatings, drug-eluting components, and materials. These innovations have improved the deliverability, performance, and safety profile of stents, leading to better outcomes and reducing the risk of restenosis and complications such as chronic inflammation and late stent thrombosis. Emerging stent technologies, such as DES with biodegradable polymer/polymer-free coatings and BAS, are viable alternatives to and can address the complications associated with the contemporary stents. BAS are a breakthrough technology that can provide transient support to the vessel and completely degrade over time.

This report focuses on the global coronary stents market for treating CAD. The global coronary stents market is determined for the 10 countries covered in the report, which are the US, France, Germany, Italy, Spain, the UK, Japan, Brazil, China, and India. This report identifies the unmet needs in the market for treating CAD that are associated with current stent technologies, provides an understanding of physicians' perceptions and decision-making process in using different types of stents, and evaluates the adoption of the different types of coronary stents in the future. From GlobalData's analysis, it is evident that DES currently have and will continue to command the largest share in the global coronary stents market. The widespread adoption of DES can be attributed to improved outcomes, the availability of long-term clinical evidence, and the reduced need for repeat intervention, thereby incurring cost savings for healthcare providers. In addition, the current adoption of emerging stent technologies, such as the next generation of DES and BAS, is

Drug-eluting stents are considered to be the gold standard of treatment and will continue to dominate the global coronary stents market in the future.

Introduction

slow. BAS, such as the Absorb BVS and DESolve, have received only CE Mark approval and are available only in selected markets. Large-scale, long-term cost-effectiveness studies need to be conducted to demonstrate their clinical efficacy, so that these innovative technologies can be integrated appropriately into the existing reimbursement systems.

2.1 Catalyst

Stent technology has revolutionized the field of interventional cardiology such that coronary stenting has become the standard of care for patients with CAD. Modern developments in PCI have led to a paradigm shift in the treatment of CAD towards stenting. Among the coronary stents, DES dominate the coronary stents market worldwide, and physicians have extensive clinical experience using these devices. Unlike bare metal stents (BMS) and covered stents (CS), DES elute an antiproliferative agent, which can significantly reduce restenosis and target lesion revascularization (TLR) rates.

Modern developments in PCI have led to a paradigm shift in the treatment of CAD towards stenting.

Vascular stent technology has evolved over the years and is used in clinical practice for different types of lesions/indications, such as *de novo* stenosis, bifurcation lesions, and small-vessel disease (SVD). Although stent technologies such as DES have reduced the risk of restenosis and the need for repeat revascularization, and also provide mechanical support to the vessel, complications such as late and very late stent thrombosis, chronic inflammation, and dependency on prolonged dual antiplatelet therapy reiterate the need for new treatment modalities. In addition, the presence of polymer coatings on DES can lead to chronic inflammation and hypersensitivity reactions, resulting in poor clinical outcomes and endangering patient safety. The next generation of coronary stents is being developed with innovative stent structures, thinner struts, more effective antiproliferative drugs, durable metal alloys, biodegradable polymer coatings, bioactive and polymer-free coatings, and fully-absorbable stent platforms. BAS offer several benefits, including eliminating the need for stent-in-stent procedures, thereby potentially reducing the need for prolonged dual antiplatelet therapy, enhanced vessel healing, and improving the feasibility of future interventions.

As more long-term clinical data demonstrating the superior therapeutic benefits of BAS and reimbursement become available, the adoption of BAS by the medical community will increase slowly in the future. As CAD is an enormous global public health and socioeconomic problem, and the use of stents continues to increase, it is important to find effective treatment modalities that ensure long-term quality results for patients. This report looks at the current coronary stents market

Introduction

for CAD in various regions, and evaluates the adoption and opportunities for these technologies in the 10 major markets (10MM).

2.2 Related Reports

- GlobalData (2012). Bioabsorbable Stents – Global Market Analysis and Forecasts, December 2012, GDME0164MAR
- GlobalData (2013). Drug Eluting Balloons – Global Market Analysis and Forecasts, September 2013, GDME0179MAR

Appendix

12.8 About MediPoint

MediPoint is the flagship product for GlobalData's Medical team. Each MediPoint report is built from the ground up by our team of healthcare analysts in the US and UK. Each report includes input from experienced physicians and leading KOLs. Running throughout each report in the series, the "What Physicians Think" quotes provide unique insight into how healthcare professionals are reacting to events within the industry, and what their responses could mean for industry strategists.

12.9 About GlobalData

GlobalData is a leading global provider of business intelligence in the healthcare industry. GlobalData provides its clients with up-to-date information and analysis on the latest developments in drug research, disease analysis, and clinical research and development. Our integrated business intelligence solutions include a range of interactive online databases, analytical tools, reports, and forecasts. Our analysis is supported by a 24/7 client support and analyst team.

GlobalData has offices in New York, San Francisco, Boston, London, India, Korea, Tokyo, Japan, Singapore, and Australia.

12.10 Disclaimer

All Rights Reserved.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form by any means, electronic, mechanical, photocopying, recording, or otherwise, without the prior permission of the publisher, GlobalData.